Branded

HORSHAM, Pa. — Patients with seasonal allergies are more likely to experience difficulty sleeping, according to results of a new survey conducted by Teva Respiratory.

WAYNE, N.J. — The Food and Drug Administration will expedite its review of an investigational drug made by Bayer HealthCare Pharmaceuticals for treating tumors of the gastrointestinal tract, the company said Tuesday.

NEW YORK — The Food and Drug Administration expects to approve an increasing number of drugs, according to published reports.

Reuters quoted FDA Center for Drug Evaluation and Research director Janet Woodcock as saying the number of drugs approved gradually could increase, already having reached a “nadir.” The report noted that 12 drugs had won approval this year so far, and Woodcock speculated that the agency would approve more than the 21 it approved last year.

WHITEHOUSE STATION, N.J. — Drug maker Merck announced that it has kicked off an initiative that includes a wide range of public education and patient support programs, as well as research efforts to help improve care for people living with chronic hepatitis C virus infections.

Merck's Hope Against Hepatitis C initiative includes a variety of public-private partnerships, educational programs and collaborative research efforts aimed at supporting the hepatitis C community.

PARIS — French drug maker Sanofi-Aventis has shortened its name to Sanofi, the company said.

The company, which acquired Cambridge, Mass.-based biotech giant Genzyme for $20.1 billion earlier this year, had planned to vote at its shareholder meeting Friday.

According to published reports, the previous name was difficult to pronounce for people in many countries.

PEAPACK, N.J. — Greenstone has introduced an authorized generic treatment for breast cancer, the generics subsidiary of Pfizer said.

The company announced the launch of exemestane tablets, an authorized generic version of Pfizer’s Aromasin. Aromasin is used to treat early breast cancer in menopausal women who already have taken the drug tamoxifen for two to three years, as well as breast cancer in women whose disease has worsened while taking tamoxifen, which is widely available as a generic.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a drug made by Novartis as the first treatment for advanced pancreatic neuroendocrine tumors, Novartis said Thursday.

Novartis announced the approval of Afinitor (everolimus), saying it marked the first approval of a drug for advanced pancreatic NET in nearly 30 years. The drug already is approved for treating cancers of the kidneys and brain.

INDIANAPOLIS — Eli Lilly announced its largest-ever education-focused grant.

The drug maker has teamed up with nonprofit group The Mind Trust to launch the Grow What Works campaign, which seeks to raise and invest $18 million in the highest-impact education organizations working in Indianapolis. Lilly invested $2.5 million for the cause.

Since its founding in 2006, The Mind Trust has been strategically building a network of the nation's best education reform organizations in Indianapolis, Lilly said.